North American Report

Acral Lentiginous Melanoma Market is Expected to Expand at a Healthy Growth Rate by 2030, States DelveInsight | Key Companies – Atreca and Bristol-Myers Squibb

 Breaking News
  • No posts were found

Acral Lentiginous Melanoma Market is Expected to Expand at a Healthy Growth Rate by 2030, States DelveInsight | Key Companies – Atreca and Bristol-Myers Squibb

January 11
19:30 2022
Acral Lentiginous Melanoma Market is Expected to Expand at a Healthy Growth Rate by 2030, States DelveInsight | Key Companies - Atreca and Bristol-Myers Squibb
Delveinsight Business Research LLP
DelveInsight’s “Acral Lentiginous Melanoma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Acral Lentiginous Melanoma Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Acral Lentiginous Melanoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acral Lentiginous Melanoma Market

Acral Lentiginous Melanoma: An Overview

According to AIM at Melanoma Foundation, Acral Lentiginous Melanoma (ALM) is a type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails. ALM starts as a slowly-enlarging flat patch of discolored skin. At first, the malignant cells remain within the epidermis—the in situ phase of melanoma, which can persist for months or years.

The melanoma becomes invasive when the melanoma cells cross the basement membrane of the epidermis, and malignant cells enter the dermis. Initial treatment of ALM generally consists of surgery to remove the skin lesion. Additional therapies such as radiation therapy or immunotherapy may then be recommended depending on the severity of the condition.

Acral Lentiginous Melanoma Market Key Facts

  • According to the study by Ciocan et al. titled “Distinctive Features of Melanoma and Its Management in Elderly Patients A Population-Based Study in France,” older patients developed nodular melanoma, lentigo malignant melanoma, or acral lentiginous melanoma more frequently.

  • According to the article by Kai et al., the incidence of ALM in the US is approximately 2‒3%.

  • As per the study by Bradford et al., approximately 37.8% of ALMs were in stage I. In men, 30.0% of ALM cases diagnosed were at stage I as compared to 41.9% in women. The highest percentage of ALM cases diagnosed at stages I and III were found in non-Hispanic whites (40.1%) and Asian/Pacific Islanders (50%), respectively. 

Acral Lentiginous Melanoma Market

As per DelveInsight, the rise in the incidence of Acral Lentiginous Melanoma will boost the market growth during the forecasted period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Acral Lentiginous Melanoma market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Acral Lentiginous Melanoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Get the PDF Sample of the Report:- Acral Lentiginous Melanoma Therapeutics Market

Acral Lentiginous Melanoma Epidemiology

The epidemiology section covers insights about the historical and current Acral Lentiginous Melanoma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Acral Lentiginous Melanoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acral Lentiginous Melanoma market or expected to get launched in the market during the study period. The analysis covers Acral Lentiginous Melanoma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Acral Lentiginous Melanoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Acral Lentiginous Melanoma Therapeutics Analysis

The current clinical pipeline of Acral Lentiginous Melanoma is weak. However, some of the key players are working toward the development of therapies for Acral Lentiginous Melanoma which includes Atreca and Bristol-Myers Squibb. 

Acral Lentiginous Melanoma Therapies Covered in the report include:

  • ATRC-101

  • Nivolumab with Ipilimumab

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:- Chronic Insomnia Therapeutics Landscape

Table of Content

1. Key Insights

2. Executive Summary 

3. Acral Lentiginous Melanoma Competitive Intelligence Analysis

4. Acral Lentiginous Melanoma Market Overview at a Glance

5. Acral Lentiginous Melanoma Disease Background and Overview

6. Acral Lentiginous Melanoma Patient Journey

7. Acral Lentiginous Melanoma Epidemiology and Patient Population

8. Acral Lentiginous Melanoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Acral Lentiginous Melanoma Unmet Needs

10. Key Endpoints of Acral Lentiginous Melanoma Treatment

11. Acral Lentiginous Melanoma Marketed Products

12. Acral Lentiginous Melanoma Emerging Therapies

13. Acral Lentiginous Melanoma Seven Major Market Analysis

14. Attribute Analysis

15. Acral Lentiginous Melanoma Market Outlook (7 major markets)

16. Acral Lentiginous Melanoma Access and Reimbursement Overview

17. KOL Views on the Acral Lentiginous Melanoma Market.

18. Acral Lentiginous Melanoma Market Drivers

19. Acral Lentiginous Melanoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States